Clinical Trials · NCT02651987

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Name: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Lanreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 99
Start date: Dec 2015
Locations: 32 sites, 10 countries
Primary endpoint: Median Progression Free Survival (PFS)

View Lanreotide compound reference